Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 549

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 1
Chunk 549
---
 January 18, 2025, the Company
caused to be deposited $37,744 into the Company’s Trust account, allowing the Company to extend the period of time it has to consummate
its initial Business Combination from January 18, 2025 to February 18, 2025. On February 18, 2025, the Company caused to be deposited
$37,744 into the Company’s Trust account, allowing the Company to extend the period of time it has to consummate its initial Business
Combination from February 18, 2025 to March 18, 2025. On March 18, 2025, the Company caused to be deposited $37,744 into the Company’s
Trust account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from March 18,
2025 to April 18, 2025.

As
of December 31, 2024, there was $3,537,744 outstanding under the Extension Loans from the Sponsor. As of March 31, 2025, there was $3,650,976
outstanding under the Extension Loans from the Sponsor.

18

Merger
Agreement with Longevity Biomedical Inc.

On
September 16, 2024, the Company, entered into a Merger Agreement”, by and among the Company, Longevity, LBI Merger Sub, Inc., and
Bradford A. Zakes, solely in the capacity as seller representative.

Pursuant
to the Merger Agreement, the parties thereto will enter into the Transactions, pursuant to which, among other things, immediately following
the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue LLC, Longevity will merge
with and into LBI Merger Sub, with Longevity as the surviving entity and becoming a wholly-owned subsidiary of the Company. At the closing
of the Transactions (the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.”
and the Company’s common stock is expected to list on the NASDAQ Capital Market under the ticker symbol “LBIO.”

The
consummation of the proposed Longevity Business Combination is subject to certain conditions as further described in the Merger Agreement.

In
connection with the execution of the Merger Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has